Status:
UNKNOWN
IVIg Therapy for Patients With Idiopathic Cardiomyopathy and Endomyocardial Biopsy Proven High PVB19 Viral Load
Lead Sponsor:
Maastricht University Medical Center
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Rationale: Parvovirus B19 (PVB19) persistence in the heart has been associated with progressive cardiac dysfunction and evolution to dilated cardiomyopathy. Objective: Whether high dose of intravenou...
Eligibility Criteria
Inclusion
- Idiopathic heart failure \<1 year.
- Optimal conventional heart failure medication \<6 months.
- PVB19 viral load \>150copies/mcg DNA in EMBs.
Exclusion
- significant (lesions \>50% stenosis) coronary artery disease.
- significant valvular disease.
- systemic diseases such as sarcoidosis, giant cell myocarditis, hemochromatosis, or systemic autoimmune diseases.
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2010
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00659386
Start Date
February 1 2009
End Date
August 1 2010
Last Update
February 4 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Maastricht
Maastricht, Maastricht, Netherlands, 6229 HX